A Phase I Study of AZD0424 Alone and in Combination in Advanced Solid Tumours

Summary

The purpose of this study is to determine the maximum tolerated dose of the oral Src/Abl inhibitor AZD0424, and to find tolerable and effective AZD0424 combination regimens for the treatment of advanced solid tumours

Timeline

Start

2012-10

Primary completion

2016-05

Completion

2016-05

Outcome

Outcome not reported

Stopped: “Single agent phase completed, insufficient supportive preclinical data to proceed with combination phase”

Publications

• Woodcock VK, Clive S, Wilson RH, Coyle VM, Stratford MRL, Folkes LK, Eastell R, Barton C, Jones P, Kazmi-Stokes S, Turner H, Halford S, Harris AL, Middleton MR. A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424. Br J Cancer. 2018 Mar 20;118(6):770-776. doi: 10.1038/bjc.2017.484. Epub 2018 Feb 13.

Drugs

Indications